Beyond monogenic disorders, gene therapy is also being applied towards acquired retinal diseases such as age-related macular degeneration and diabetic retinopathy, where sustained intraocular production of anti-VEGF proteins through gene delivery could reduce treatment burden [6]. This evidence concerns the gene VEGFA and diabetic retinopathy.